Your browser doesn't support javascript.
loading
An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival.
Mannavola, Francesco; Mandala, Mario; Todisco, Annalisa; Sileni, Vanna Chiarion; Palla, Marco; Minisini, Alessandro Marco; Pala, Laura; Morgese, Francesca; Di Guardo, Lorenza; Stucci, Luigia Stefania; Guida, Michele; Indini, Alice; Quaglino, Pietro; Ferraresi, Virginia; Marconcini, Riccardo; Tronconi, Maria Chiara; Rossi, Ernesto; Nigro, Olga; Occelli, Marcella; Cortellini, Alessio; Quadrini, Silvia; Palmieri, Giuseppe; Pigozzo, Jacopo; Ascierto, Paolo Antonio; Vitale, Maria Grazia; Strippoli, Sabino; Ferrucci, Pier Francesco; Berardi, Rossana; Randon, Giovanni; Cardone, Pietro; Schinzari, Giovanni; Silvestris, Franco; Tucci, Marco.
Afiliação
  • Mannavola F; Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy.
  • Mandala M; Medical Oncology Unit, Department of Oncology and Hematology, Azienda Ospedaliera Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Todisco A; Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy.
  • Sileni VC; Melanoma Oncology Unit, Veneto Institute of Oncology, Scientific Institute for Research, Hospitalization and Healthcare, Padua, Italy.
  • Palla M; Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
  • Minisini AM; Department of Oncology, Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Italy.
  • Pala L; Division of Melanoma, Sarcoma and Rare Tumors, European Institute of Oncology, Scientific Institute for Research, Hospitalization and Healthcare, Milan, Italy.
  • Morgese F; Oncology Clinic, Università Politecnica delle Marche, Ancona, Italy.
  • Di Guardo L; Melanoma Medical Oncology Unit, Department of Medical Oncology and Hematology, National Institute of Tumori, Milan, Italy.
  • Stucci LS; Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy.
  • Guida M; IRCCS Giovanni Paolo II, Cancer Institute, Bari, Italy.
  • Indini A; Medical Oncology Unit, Department of Oncology and Hematology, Azienda Ospedaliera Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Quaglino P; Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
  • Ferraresi V; First Division of Medical Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Marconcini R; Medical Oncology Department, Santa Chiara Hospital, University of Pisa, Pisa, Italy.
  • Tronconi MC; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy.
  • Rossi E; Medical Oncology, Fondazione Policlinico Universitario 'Agostino Gemelli' IRCCS, Rome, Italy.
  • Nigro O; Medical Oncology, ASST-Sette Laghi, Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
  • Occelli M; Medical Oncology Unit, Santa Croce and Carle Teaching Hospital, Cuneo, Italy.
  • Cortellini A; Department of Biotechnological and Applied Clinical Sciences, San Salvatore Hospital, University of L'Aquila, L'Aquila, Italy.
  • Quadrini S; Medical Oncology Unit, Azienda Sanitaria Locale Frosinone, Frosinone, Italy.
  • Palmieri G; Unit of Cancer Genetics, Institute of Genetic and Biomedical Research, National Research Council, Sassari, Italy.
  • Pigozzo J; Melanoma Oncology Unit, Veneto Institute of Oncology, Scientific Institute for Research, Hospitalization and Healthcare, Padua, Italy.
  • Ascierto PA; Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
  • Vitale MG; Department of Oncology, Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Italy.
  • Strippoli S; IRCCS Giovanni Paolo II, Cancer Institute, Bari, Italy.
  • Ferrucci PF; Division of Melanoma, Sarcoma and Rare Tumors, European Institute of Oncology, Scientific Institute for Research, Hospitalization and Healthcare, Milan, Italy.
  • Berardi R; Oncology Clinic, Università Politecnica delle Marche, Ancona, Italy.
  • Randon G; Melanoma Medical Oncology Unit, Department of Medical Oncology and Hematology, National Institute of Tumori, Milan, Italy.
  • Cardone P; Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
  • Schinzari G; Medical Oncology, Fondazione Policlinico Universitario 'Agostino Gemelli' IRCCS, Rome, Italy.
  • Silvestris F; Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy.
  • Tucci M; Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy.
Front Oncol ; 10: 1652, 2020.
Article em En | MEDLINE | ID: mdl-33042809
BACKGROUND: We performed a multicenter retrospective observational study to investigate the impact of clinical-pathological features and therapeutic strategies on both the complications and survival of patients with bone metastases (BMs) from malignant melanoma. PATIENTS AND METHODS: A total of 305 patients with melanoma and radiological evidence of BMs were retrospectively enrolled from 19 Italian centers. All patients received conventional treatments in accordance with each own treating physician's practice. Both univariate and multivariate models were used to explore the impact of melanoma features, including skeletal-related events (SREs), and different treatments on both overall survival (OS) and time-to-SREs. The chi-squared test evaluated the suitability of several parameters to predict the occurrence of SREs. RESULTS: Eighty-three percent of patients had metachronous BMs. The prevalent (90%) bone metastatic site was the spine, while 45% had involvement of the appendicular skeleton. Forty-seven percent experienced at least one SRE, including palliative radiotherapy (RT) in 37% of cases. No melanoma-associated factor was predictive of the development of SREs, although patients receiving early treatment with bone-targeted agents showed 62% lower risk and delayed time of SRE occurrence. Median OS from the diagnosis of bone metastasis was 10.7 months. The multivariate analysis revealed as independent prognostic factors the number of BMs, number of metastatic organs, baseline lactate dehydrogenase levels, and treatment with targeted therapy or immunotherapy. Subgroup analyses showed the best OS (median = 16.5 months) in the subset of patients receiving both immunotherapy and palliative RT. CONCLUSION: Based on our results, patients undergoing immunotherapy and palliative RT showed an OS benefit suggestive of a possible additive effect. The apparent protective role of bone targeting agent use on SREs observed in our analysis should deserve prospective evaluation.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article